1-5 of 5
David Dejardin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Ph.D., Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, M. Brigid Bradley-Garelik, MD, David Dejardin, Neil P. Shah, MD, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 2286.
https://doi.org/10.1182/blood.V116.21.2286.2286
Published: 2010
Journal Articles

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Charles A. Schiffer, Jorge E. Cortes, Giuseppe Saglio, Philipp le Coutre, Francois Guilhot, Erkut Bahceci, David Dejardin, Neil P. Shah
Journal: Blood
Blood (2010) 116 (21): 358.
https://doi.org/10.1182/blood.V116.21.358.358
Published: 2010
Journal Articles

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

H. Jean Khoury, MD, FACP, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, Neil P. Shah, MD, Ph.D., M. Brigid Bradley-Garelik, MD, David Dejardin, Andreas Hochhaus, MD
Journal: Blood
Blood (2010) 116 (21): 3421.
https://doi.org/10.1182/blood.V116.21.3421.3421
Published: 2010
Journal Articles

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Francois Guilhot, Hagop Kantarjian, MD, Neil P. Shah, Andreas Hochhaus, M. Brigid Bradley-Garelik, David Dejardin, Jorge E. Cortes, MD
Journal: Blood
Blood (2010) 116 (21): 2295.
https://doi.org/10.1182/blood.V116.21.2295.2295
Published: 2010
Journal Articles

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Hagop M. Kantarjian, MD, Philippe Rousselot, MD, Ricardo Pasquini, MD, Nelson Hamerschlak, MD, Jerzy Holowiecki, MD, David Dejardin, Eric Bleickardt, MD, Neil P. Shah, MD
Journal: Blood
Blood (2007) 110 (11): 736.
https://doi.org/10.1182/blood.V110.11.736.736
Published: 2007